---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221596"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2026-05-13T20:05:34+00:00"
generated_at: "2026-05-13T22:10:09.272753+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

## Summary
- Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
- Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.
- Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.
- Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.
- FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained.

## SEC filing metadata
- accession: 0001193125-26-221596
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2026-05-13T20:05:34+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/0001193125-26-221596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/clpt-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221596
- JSON: https://secwatch.observer/filing/0001193125-26-221596.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.